DIRECTED SHARE ISSUE IN SCN PROLONGED

(NGM:SCN)

The Board of Scandinavian Clinical Nutrition AB (SCN) has decided to prolong the ongoing directed share issue until January 16, 2009, due to the upcoming holidays. As a consequence, the subscription price has been adjusted to SEK 5.

Due to practical reasons in connection with the holidays, the Board of SCN has decided to prolong the subscription time in the ongoing directed share issue until January 16, 2009. The subscription price has been recalculated to reflect the current stock price, and the new price is set to SEK 5.

The other terms and conditions remain the same.

For more information, please contact:

Carsten Waern, CEO, cw@scnutrition.com, +45 2090 8888

Ulf Söderberg, Chairman of the Board, us@scnutrition.com, +46 708 13 22 81

Scandinavian Clinical Nutrition AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se). For more information, please visit www.scnutrition.com.